Key result
Atrial Aveir VR leadless pacemaker demonstrates successful implantation and stable 3-month performance in congenital heart disease.
Why the study?
Pediatric patients with congenital heart disease repair may develop sinus node dysfunction, and leadless pacemakers have been used for ventricular pacing but not previously reported for atrial pacing in adolescents.
Is atrial implantation of a leadless pacemaker feasible and safe in an adolescent with congenital heart disease and sinus node dysfunction?
Case Report (n=1)
No
Is atrial implantation of a leadless pacemaker feasible and safe in an adolescent with congenital heart disease and sinus node dysfunction?
Atrial implantation of a leadless pacemaker is feasible and provides stable pacing parameters without complications in an adolescent with congenital heart disease.
May support atrial leadless pacing feasibility in adolescents with CHD; hypothesis-generating, requiring prospective trials before adoption.
INTRODUCTION: Pediatric patients with congenital heart disease repair may develop sinus node dysfunction. Leadless pacemakers have provided an alternative option to transvenous and epicardial device implants for pediatric patients in need of ventricular pacing. We describe the first adolescent patient to receive a leadless pacemaker in the atrium due to symptomatic sinus pauses. METHODS: The study was approved by the internal review board of the University of California at Davis. Femoral vein implant was performed of an Aveir VR due to the higher impedance and larger battery capacity. RESULTS: The 16-year-old male with dextro-transposition of the great arteries and ventricular septal defect repair had an uncomplicated atrial appendage implant of an Atrial Aveir VR, under transesophageal echocardiographic guidance. Three-month follow-up demonstrated stable threshold of 0.5 V @ 0.2 milliseconds, impedance of 720 Ω and sensing of 9.1 mV, with 10 % pacing and predicted battery longevity of 22.8 years. CONCLUSION: Atrial implant of a leadless pacemaker is possible in the older pediatric population without complications, including of the Aveir VR.
No takes yet. Share an insight, caveat, or question.
Daniel Lee Cortez (2024) conducted a case report in Sinus node dysfunction in congenital heart disease (n=1). Aveir VR leadless pacemaker was evaluated on Device performance and safety (impedance, sensing, threshold, complications). Atrial implantation of the Aveir VR leadless pacemaker was successfully performed without complications in a 16-year-old male with congenital heart disease and symptomatic sinus node dysfunction, demonstrating stable parameters at 3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: